厄贝沙坦和培哚普利对轻中度原发性高血压凝血纤溶系统的影响

Effects of Irbesartan and Perindopril on Coagulative and Fibrinolytic System in Essential Hypertension

目的观察厄贝沙坦和培哚普利在降压的同时,对原发性高血压凝血纤溶系统的影响。方法测定48例轻中度原发性高血压患者及23例对照组血浆纤维蛋白原(Fbg)、D二聚体(DD)、抗凝血酶Ⅲ(ATⅢ)水平。将48例轻中度高血压患者随机分成2组,厄贝沙坦组22例,150mg/d口服;培哚普利组26例4mg/d口服,治疗后6周测Fbg、DD、ATⅢ。结果高血压组治疗前Fbg、DD显著高于对照组(P均<0.01),ATⅢ低于对照组(P<0.05)。药物治疗后2组Fbg、DD均较用药前降低,差异有显著性(P均<0.01),ATⅢ均升高(P<0.05)。结论厄贝沙坦和培哚普利在控制血压的同时能改善高血压患者的高凝和继发性纤溶亢进状态。

Objective To study the effects of Irbesartan and Perindopril on coagulative and fibrinolytic system in essential hypertension. Methods Plasma levels of fibrinogen(Fbg), D-dimer(D-D), antithrombin Ⅲ(AT-Ⅲ) were examined before and after treatment in 48 patients with mild to moderate essential hypertension and 23 controls. 48 patients were randomlyassigned to Irbesartan(150 mg/d, n=22) or Perindopril(4 mg/d, n=26) for 6 weeks. Results Compared with controls, the levels of Fbg, D-D were significantly higher(P<0.01, respectively), and the levels of AT-Ⅲ were significantly lower (P<0.05) in patients with essential hypertension. After 6 weeks'treatment with Irbesartan and Perindopril, significantly reduction in blood pressure and levels of Fbg, D-D(P<0.01, respectively) was found which was associated with elevation in levels of AT-Ⅲ(P<0.05). Conclusion Antihypertensive treatment with Irbesartan and Perindopril could improve the impairedcoagulative and fibrinolytic system in patients with essential hypertension.